Actively Recruiting

Early Phase 1
Age: 0Months - 24Months
All Genders
NCT06272149

An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher Disease

Led by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Updated on 2024-02-22

6

Participants Needed

1

Research Sites

313 weeks

Total Duration

On this page

Sponsors

X

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Lead Sponsor

S

Shanghai Vitalgen BioPharma Co., Ltd.

Collaborating Sponsor

AI-Summary

What this Trial Is About

This exploratory trial is to prove the tolerability and safety of VGN-R08b to treat infants with type II Gaucher disease.

CONDITIONS

Official Title

An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher Disease

Who Can Participate

Age: 0Months - 24Months
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Infants aged 24 months or younger
  • Confirmed Gaucher disease diagnosis by GCase enzyme activity test with GBA1 biallelic mutations
  • Presence of neurological signs or symptoms consistent with type II Gaucher disease
  • Parent or legal guardian consent for study enrollment
  • Parent or legal guardian agreement to provide disease information and assist with symptom assessments
Not Eligible

You will not qualify if you...

  • Diagnosis of other significant central nervous system diseases aside from type II Gaucher disease
  • Ability to walk independently
  • Severe visceral symptoms posing unacceptable risk or study interference as judged by the investigator
  • Active infections including HIV, HBV, HCV, or syphilis
  • Stable treatment with enzyme replacement, substrate reduction, or ambroxol for less than 2 months before enrollment
  • Use of strong cytochrome CYP3A4 or P-glycoprotein inhibitors or inducers
  • Prior gene or cell therapy
  • Live vaccinations within the previous 4 weeks
  • Use of systemic immunosuppressants or corticosteroids excluding topical dermatological treatments
  • Presence of anti-AAV9 neutralizing antibodies above a specified level
  • Brain MRI abnormalities preventing intracisternal injection
  • Contraindications to sedation for surgery or imaging
  • Other significant medical conditions posing unacceptable risks or interfering with study participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China, 200097

Actively Recruiting

Loading map...

Research Team

Z

Zhang Huiwen, Dr.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here